Skip to content

Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery

Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07399691
Acronym
SCBPBs
Enrollment
54
Registered
2026-02-10
Start date
2024-01-01
Completion date
2024-04-30
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dexamethasone, Bupivacaine, Upper Limb Surgery

Keywords

dexamethasone,Bupivacaine,Analgesia,supraclavicular block

Brief summary

* SCBPBs provides optimal conditions for procedures performed below the mid-upper arm (elbow, forearm, wrist, hand) due to its high success rate and ease of access. * Dexamethasone, when administered perineurally as an adjuvant for a supraclavicular block, demonstrated early onset of sensory and motor block, a prolonged duration of sensory and motor block, and a lower number of rescue analgesics as compared to bupivacaine alone. * A combination of dexamethasone and bupivacaine is paramount in adult orthopeadic patient to enhance the efficacy of pain management under ultrasound-guided supraclavicular brachial plexus block.

Interventions

Adding 8 mg of dexamethasone to bupivacaine for ultrasound-guided supraclavicular block

Sponsors

Arsi University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular block.

Exclusion criteria

Patients who refused, used local anaesthetics other than bupivacaine, had multiple traumas, addition of another additive, bleeding disorders, patients diagnosed with chronic pain, cancer pain, local infection at the injection site, history of local anaesthetic allergy, patients with anxiety, and inability to comprehend or use the pain rating scale

Design outcomes

Primary

MeasureTime frameDescription
The onset of sensory and motor blockade, and the duration of sensory and motor blockade in minutes.with in the first 24hrs after procedure1. The onset of sensory: the period between injecting a study solution and losing sensation to a pinprick at every nerve distribution 2. The onset of motor block: The duration between the injection of the study solution and paresis in every nerve distribution. 3. duration of sensory: the period between the onset of a sensory block and the complete restoration of sensation. 4. Duration of motor block: the period between the onset of a motor block and the complete restoration of motor function.

Secondary

MeasureTime frameDescription
postoperative pain score by a visual analogue scalewith in the first 24 hrs after procedureThis assesses behavioural or subjective phenomena by having the participant choose an alternative from a gradient ranging from 0 = (no pain) to 100 = worst possible pain. Based on the VAS score, 0-20 mm = no pain; 21-40 mm = mild pain; 41-60 mm = moderate pain; 61-80 mm = severe pain; and 81-100 mm = the worst pain imaginable
First analgesic request timeWith in the first 24 hrs after surgeryThe first postoperative period, when patients require pain treatment if the visual analogue score is\>4

Countries

Ethiopia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026